Results from a study that were presented at the European Society for Medical Oncology’s Congress have shown that the investigational drug for prostate cancer INO-5150 may be able to slow the progression of the disease. For more detailed information about these results, you can view the source press release at Inovio’s website here.
About Prostate Cancer
Prostate cancer is one of the most common forms of cancer in men. The prostate is a small gland in the pelvis of males. Often, prostate cancer develops very slowly, and people with prostate cancer may not notice any symptoms for a long time. To read more about prostate cancer, click here.
According to Inovio’s website, INO-5150 is a DNA immunotherapy that is designed to target prostate-specific membrane antigen and prostate-specific antigen. So far, the drug has shown encouraging results in multiple animal studies, and, based on this, a clinical program that tests the drug in humans began in 2015.
The Study Results
A Phase 1b study of INO-5150 in patients with biochemically relapsed prostate cancer was recently completed. According to Inovio’s announcement, more than three quarters (86%) of patients were still progression-free at week 72 in the study, which is particularly promising given the high-risk patient population taking part in the study. In addition, the study found that most people showed a slowing of Prostate-Specific Doubling Time, which is a measure of disease progression. Analyses also showed that 77% of patients showed immunogenicity (provoking an immune response) based on several assessments.